FIG. 1 - Geometric mean titers (GMTs) for anti-HA antibody at different timepoints (ATP cohort for immunogenicity)




FIG. 2 - SPR for HI antibody titer with 95% confidence interval at day 0 and day 21 (ATP cohort for immunogenicity)




FIG. 3 - SCR for HI antibody titer with 95% confidence interval at day 21 (ATP cohort for immunogenicity)




FIG. 4 - SCF for HI antibody titer with 95% confidence interval at day 21 (ATP cohort for immunogenicity)




FIG. 5 Haemagglutinin Inhibition test (GMT +/- IC95) in BALB/c mice primed with heterosubtypic strains (dose range AS03)

Fig. 5A – Anti-A/New Caledonia/20/99 HI titers




Fig. 5B – Anti-A/Panama/2007/99 HI titers




Fig. 5C – Anti-B/Shandong/7/97 HI titers




FIG. 6 Haemagglutinin Inhibition test (GMT +/- IC95) in C57Bl/6 mice primed with heterosubtypic strains (dose range AS03)






FIG. 7 Cellular immune response (CD4+ T cell) in PBMC from C57Bl/6 mice primed with heterosubtypic strains (dose range AS03)



	Trivalent split Plain	Trivalent split AS03	Trivalent split AS03/2	Trivalent split AS03/5	PBS
CD4+IL2+	0.06	0.28	0.19	0.13	0.04
CD4+IL2+INFg+	0.01	0.04	0.02	0.03	0.01
CD4+INFg+	0.01	0.08	0.07	0.04	0.01

FIG. 8 Cellular immune response (CD4+ T cell) in PBMC from C57Bl/6 mice primed with heterosubtypic strains and immunized with low dose antigen (0.5 µg) adjuvanted with dose range AS03



	Trivalent split Plain	Trivalent split AS03	Trivalent split AS03/2	Trivalent split AS03/5	PBS
CD4+IL2+	0.10	0.13	0.18	0.37	0.03
CD4+IL2+INFg+	0.06	0.02	0.02	0.04	0.02
CD4+INFg+	0.01	0.06	0.06	0.09	0.03

FIG. 9 H5N1-specific serum Ig ELISA titers (A and B) and anti-H5N1 IgG1 (C and D) and IgG2b (E and F) isotypic responses on day 14 post-immunization (GMT +/- IC95) for two different antigen dose: 1.5 µg (A, C and E) or 0.38 µg (B, D and F)

Fig. 9A




Fig. 9B




Fig. 9C



Anti A/H5N1 ELISA midpoint: IgG1 response
ELISA Midpoint (GMT +/- IC95)
100000
80000
60000
40000
20000
0
H5N1 split plain (1.5 µg)
H5N1 split 2x AS03 (1.5 µg)
H5N1 split AS03 (1.5 µg)
H5N1 split AS03/2 (1.5 µg)
H5N1 split AS03/5 (1.5 µg)
PBS

Fig. 9D



Anti A/H5N1 ELISA midpoint: IgG1 response
ELISA Midpoint (GMT +/- IC95)
100000
75000
50000
25000
0
H5N1 split plain (0.38 µg)
H5N1 split 2x AS03 (0.38 µg)
H5N1 split AS03 (0.38 µg)
H5N1 split AS03/2 (0.38 µg)
H5N1 split AS03/5 (0.38 µg)
PBS

Fig. 9E



Anti A/H5N1 ELISA midpoint: IgG2b response
ELISA Midpoint (GMT +/- IC95)
20000
16000
12000
8000
4000
0
H5N1 split plain (1.5 µg)
H5N1 split 2x AS03 (1.5 µg)
H5N1 split AS03 (1.5 µg)
H5N1 split AS03/2 (1.5 µg)
H5N1 split AS03/5 (1.5 µg)
PBS

Fig. 9F



Anti A/H5N1 ELISA midpoint: IgG2b response
ELISA Midpoint (GMT +/- IC95)
30000
25000
20000
15000
10000
5000
0
H5N1 split plain (0.38 µg)
H5N1 split 2x AS03 (0.38 µg)
H5N1 split AS03 (0.38 µg)
H5N1 split AS03/2 (0.38 µg)
H5N1 split AS03/5 (0.38 µg)
PBS

FIG.10 Hemagglutination inhibition test (GMT +/- IC95) on day 21 post-immunization (GMT +/- IC95) for two different antigen dose: 1.5 µg (A) or 0.38 µg (B).

Fig. 10A




Fig. 10B






FIG. 11 Cellular immune response (CD4+ T cell) in naïve C57Bl/6 mice immunized with different dose of H5N1 vaccine (1.5 or 0.38 µg) adjuvanted with dose range AS03: (A) 1.5 µg Ag or (B) 0.38 µg Ag.

Fig. 11A




	H5N1 split plain	H5N1 split 2x AS03	H5N1 split AS03	H5N1 split AS03/2	H5N1 split AS03/5	PBS
CD4+IL2+	0.06	0.39	0.43	0.26	0.10	0.01
CD4+IL2+INFg+	0.03	0.02	0.03	0.03	0.03	0.01
CD4+INFg+	0.03	0.03	0.03	0.03	0.03	0.03

Fig. 11B



	H5N1 split plain	H5N1 split 2x AS03	H5N1 split AS03	H5N1 split AS03/2	H5N1 split AS03/5	PBS
CD4+IL2+	0.03	0.64	0.45	0.48	0.42	0.01
CD4+IL2+INFg+	0.03	0.03	0.05	0.03	0.03	0.01
CD4+INFg+	0.03	0.03	0.03	0.03	0.03	0.03


FIG. 12 Haemagglutinin Inhibition test (GMT +/- IC95) in pigs primed with homologous strains (dose range AS03)



* Group with statistically significant difference compared to the plain.


FIG. 13 Haemagglutinin Inhibition test (GMT +/- IC95) in C57Bl/6 naïve mice immunized with TIV or QIV plain or adjuvanted with AS03 or AS03/2.

Fig. 13A – Anti-B/Shangdong/7/97 (B/Victoria-like virus) HI titers



	TIV Plain	TIV AS03	TIV AS03/2	QIV Plain	QIV AS03	QIV AS03/2	PBS
D28 Post-I	10	320	320	10	320	320	10
D21 Post-II	17	1689	1040	12	970	844	14


Fig. 13B – Anti-B/Jiangsu/10/03 (B/Yamagata-like virus) HI titers



	TIV Plain	TIV AS03	TIV AS03/2	QIV Plain	QIV AS03	QIV AS03/2	PBS
D28 Post-I	10	10	10	10	80	40	10
D21 Post-II	10	15	19	14	485	485	17


FIG. 14 Haemagglutinin Inhibition test (GMT +/- IC95) in C57Bl/6 mice primed with a B/Victoria-like virus and immunized with TIV or QIV plain or adjuvanted with AS03 or AS03/2.

Fig. 14A – Anti-B/Shangdong/7/97 (B/Victoria-like virus) HI titers



	TIV Plain	TIV AS03	TIV AS03/2	QIV Plain	QIV AS03	QIV AS03/2	PBS
D28 Post-Prim	10	10	10	10	10	10	10
D21 Post-Imm	92	557	394	130	686	422	16

Fig. 14B – Anti-B/Jiangsu/10/03 (B/Yamagata-like virus) HI titers



	TIV Plain	TIV AS03	TIV AS03/2	QIV Plain	QIV AS03	QIV AS03/2	PBS
D28 Post-Prim	10	10	10	10	10	10	10
D21 Post-Imm	10	13	13	26	106	80	11

FIG. 15 - GMTs for HI antibody titer at d0 and d21




FIG. 16 - Seroprotection rates (SPR) for HI antibody titer at D0 and D21




FIG. 17A - Seroconversion rate (SCR) for HI antibody titer at PI(DAY21)




FIG. 17B - SCR for HI antibody titer at PI(DAY21) by age category




FIG. 18A - Seroconversion factor (SCF) for HI antibody titer at PI(DAY21)




FIG. 18B - SCF for HI antibody titer at PI(DAY21) by age category





FIG. 19 - GMTs for HI antibody titer at d0 and d21






B/Malaysia
GMTs with 95% CI
1000
100
10
1
PRE
POST
AS03_1_4
AS03_1_2
AS03_1_1
AS25_1_4
AS25_1_2
AS25_1_1
AS50_1_4
AS50_1_2
Flu_ELD
Flu_YNG

FIG. 20 - SPR for HI antibody titer with 95% confidence interval at days 0 and 21 (ATP cohort for immunogenicity HI)






FIG. 21 - Seroconversion rate (SCR) for HI antibody titer at PI(DAY21)




FIG. 22 - SCF for HI antibody titer with 95% CI at day 21 (ATP cohort for immunogenicity HI)




FIG. 23 - Cytokine-positive CD4 T-cells for pooled strains at D0 and D21 (ATP cohort for CMI)




FIG. 24 - Percentage of subjects reporting related solicited and unsolicited symptoms (all grades / grade 3) during the 7-day (Days 0-6) post-vaccination period (Total vaccinated cohort)

